UBS Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q4
– Sell
-1,900
Closed -$6K – 9811
2014
Q3
$6K Buy
1,900
+1,500
+375% +$3.92K ﹤0.01% 9271
2014
Q2
$1K Sell
400
-1,000
-71% -$2.14K ﹤0.01% 10194
2014
Q1
$3K Buy
+1,400
New +$2.93K ﹤0.01% 9825

Other funds holding CPRX

UBS Group's CPRX Position: Q3 2026 in Review

UBS Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 1,453,726 shares — an estimated $45.7M sold.

UBS Group first reported a position in CPRX in Q2 2013 and held it in 38 quarters. The position peaked at $45.7M in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • UBS Group reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • UBS Group sold 1,453,726 Catalyst Pharmaceutical shares in Q3 2026, an estimated $45.7M.
  • UBS Group first reported a position in Catalyst Pharmaceutical in Q2 2013 and held it in 38 quarters.
  • UBS Group's Catalyst Pharmaceutical position peaked at $45.7M in Q2 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.